ENDRA Life Sciences (NDRA)
(Delayed Data from NSDQ)
$0.20 USD
-0.01 (-6.77%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $0.21 +0.01 (6.60%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for ENDRA Life Sciences Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 11 | 13 | 12 | 12 | 11 |
Income After Depreciation & Amortization | -11 | -13 | -12 | -12 | -11 |
Non-Operating Income | 0 | 0 | 0 | 0 | -2 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -10 | -13 | -11 | -12 | -13 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -10 | -13 | -11 | -12 | -13 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -10 | -13 | -11 | -12 | -13 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -10 | -13 | -11 | -11 | -8 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 3 |
Income After Depreciation & Amortization | -11 | -13 | -12 | -12 | -11 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 0.13 | 0.06 | 0.04 | 0.02 | 0.01 |
Diluted EPS Before Non-Recurring Items | -79.00 | -228.00 | -280.00 | -630.00 | -2,340.00 |
Diluted Net EPS (GAAP) | -79.00 | -228.00 | -280.00 | -630.00 | -2,340.00 |
Fiscal Year end for ENDRA Life Sciences Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 2.23 | 2.78 | 1.46 | 3.13 | 2.99 |
Income After SG&A, R&D, and Dept/Amort Expenses | -2.23 | -2.78 | -1.46 | -3.13 | -2.99 |
Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.03 | 0.44 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -2.23 | -2.78 | -1.46 | -3.10 | -2.56 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -2.23 | -2.78 | -1.46 | -3.10 | -2.56 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -2.23 | -2.78 | -1.46 | -3.10 | -2.56 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 0.55 | 0.22 | 0.18 | 0.15 | 0.12 |
Diluted EPS Before Non-Recurring Items | -4.00 | -13.00 | -8.50 | -20.00 | -21.50 |
Diluted Net EPS (GAAP) | -4.00 | -13.00 | 9.00 | -20.00 | -21.50 |